Keensight Capital Acquires Inke from Neuraxpharm
May 1, 2023
Keensight Capital has signed a binding agreement to acquire Inke, a Spain-based specialist developer and manufacturer of inhalation active pharmaceutical ingredients (APIs), from Neuraxpharm Group; financial terms were not disclosed and the deal is expected to close in May 2023. Neuraxpharm divested Inke to sharpen its focus on CNS therapies, while Keensight will support Inke's management team to expand its footprint, broaden its offering and grow its product portfolio.
- Buyers
- Keensight Capital
- Targets
- Inke
- Sellers
- Neuraxpharm Group
- Industry
- Pharmaceuticals
- Location
- Catalonia, Spain
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Inke Acquires Pharmanoid from Gentec Pharmaceutical Group
December 18, 2025
Pharmaceuticals
Inke, supported by Keensight Capital, has acquired Pharmanoid, a specialized HPAPI manufacturing site focused on ophthalmic active pharmaceutical ingredients, from Gentec Pharmaceutical Group. The acquisition expands Inke's HPAPI capabilities beyond respiratory APIs and strengthens its position in ophthalmology and other therapeutic areas.
-
Keensight Capital Agrees to Acquire Quanos Solutions from IK Partners
December 20, 2022
Software
Keensight Capital has signed an agreement to acquire Quanos Solutions GmbH from IK Partners' IK Small Cap II Fund. Quanos, headquartered in Nuremberg, Germany, is a provider of industrial aftersales and digital technical documentation software (around 270 employees and 1,000+ customers); Keensight will support the company’s next phase of growth, expanding its product suite, market penetration and international reach. Financial terms were not disclosed and the deal is subject to customary approvals.
-
Keensight Capital Invests in CatSci Ltd
January 15, 2022
Healthcare Services
Keensight Capital has made a growth investment in CatSci Ltd, a Cardiff‑headquartered Contract Research Organisation (CRO) formed as a 2010 spin‑out from AstraZeneca. Keensight will invest alongside CatSci founders, senior management and employees to support the company's continued growth and capability expansion in small‑molecule and oligonucleotide CMC development and scale‑up.
-
Keensight Capital Acquires Majority Stake in Biovian
May 23, 2018
Biotechnology
Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.
-
Keensight Capital Acquires Majority Stake in Axxam
July 28, 2022
Biotechnology
Keensight Capital has agreed to acquire a majority stake in Axxam, an Italian innovative partner research organization (iPRO) headquartered in Milan, investing alongside Axxam's management. The sellers include current shareholders such as Bayer SpA and Zambon Company SpA; Axxam employs around 180 people and reported roughly €30 million of sales in 2021. Keensight intends to support the management team to accelerate growth and further develop Axxam's discovery capabilities.
-
Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
May 25, 2021
Healthcare Services
Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.